Singapore’s ASLAN Pharma completes $33m IPO in Taiwan

HiFiBiO Therapeutics
A biological testing process underway at a personal products lab. Photo: Bloomberg

Singapore-headquartered biotechnology company ASLAN Pharmaceuticals, which focuses on the development of immunotherapies and targeted agents for Asia prevalent tumour types, has concluded an initial public offering (IPO) of common shares via public lottery.

Continue reading this story with a subscription to DealStreetAsia.